EU agency reviews Roche’s Avastin in breast cancer

	Tweet

European healthcare regulators are reviewing the benefits of Roche’s top-selling Avastin drug in breast cancer in the light of fresh clinical data, casting more uncertainty over its prospects.

The news comes as investors await a decision from U.S. authorities on whether to revoke Avastin’s label in advanced breast cancer and follows a series of setbacks for the treatment so far this year.

The U.S. Food and Drug Administration is also considering whether to expand Avastin’s label in the United States to allow the drug to be used with other chemotherapies.

The European Medicines Agency said on Friday it had started a review of the benefits and risks of Avastin after Roche submitted a study to support its application of Avastin to treat breast cancer with anthracycline-based or capecitabine cytotoxic chemotherapy.

In comparison with results of previous studies, the agency said the latest study pointed to inconsistencies between different trials, particularly in terms of efficacy.

Roche said it was committed to working closely with EMA’s Committee for Medicinal Products for Human Use (CHMP) to make sure it had all the information it required for the review of Avastin in the first-line treatment of metastatic breast cancer.

The CHMP opinion on this label expansion is expected later this year, Roche said, adding the current use of Avastin in its licensed indications, including for the treatment of patients with metastatic breast cancer, was not affected by the review.

SETBACKS

Avastin, which brought in sales of over $6 billion for Roche last year, was once tipped to become the world’s biggest selling drug by 2014, but its prospects have faded after doubts over its benefits in breast cancer and after it failed in clinical trials for prostate and stomach cancer.

Roche, the world’s largest maker of cancer drugs, may have to grapple with a hefty dent to sales in the United States if the FDA decides to follow the advice of an advisory panel to remove the drug’s current approval for breast cancer.

About $1 billion of Avastin’s sales come from breast cancer uses, analysts estimate. The product is Roche’s top-selling drug, accounting for 13 percent of 2009 sales.

There is no set timeline for an FDA ruling on whether to revoke the breast cancer approval. If the FDA pulls it, the drug would remain on the market with clearance for colon, lung, brain and kidney cancers.

###

By Katie Reid

ZURICH (Reuters)

RELATED STORIES:
Over-the-counter anesthetic gel puts the squeeze on mammogram pain   Metabolic syndrome predicts breast cancer relapse   Cell of Origin Identified for Common Type of Breast Cancer   Common transplant drug inhibits breast cancer growth, UNC laboratory study shows   Women with Both Triple Negative Breast Cancer and BRCA Mutations Have Lower Risk of Recurrence   Benefit of novel drug in breast cancer seen in blood within weeks   Ultrasound helps catch cancer in higher-risk women   Acupuncture reduces side effects of breast cancer treatment as much as conventional drug therapy   New evidence of hormone therapy causing breast cancer, Stanford professor says   Walking Can Decrease Breast Cancer Recurrence 40 Percent   Many breast cancer patients take high doses of antioxidants despite possible consequences   Do False-Positive Mammograms Predict Cancer Risk?   Contrast agent puts new light on diagnosing breast cancer   Breast cancer kills more uninsured blacks   Scientists Develop New Therapy for HER2-Positive Breast Cancer   New screening technique could provide more reliable breast cancer detection   Genetic testing helped breast cancer survivor   Breast Cancer Patients with Diabetes More Likely to Die   Parsley, Celery Carry Crucial Component for Fight Against Breast Cancer, MU Researcher Finds   Low income linked to poorer breast cancer survival   Young Breast Cancer Patients Face Unique Risks and Issues   Breast cancer: A new treatment avenue identified

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]